{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Recombinant+GM-CSF",
    "query": {
      "intervention": "Recombinant GM-CSF"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 108,
    "total_pages": 11,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Recombinant+GM-CSF&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-04T03:23:43.050Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00005576",
      "title": "Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Disseminated Neuroblastoma",
        "Recurrent Neuroblastoma",
        "Regional Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "monoclonal antibody Ch14.18",
          "type": "BIOLOGICAL"
        },
        {
          "name": "isotretinoin",
          "type": "DRUG"
        },
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 6,
      "start_date": "2001-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-16",
      "last_synced_at": "2026-09-04T03:23:43.050Z",
      "location_count": 1,
      "location_summary": "Arcadia, California",
      "locations": [
        {
          "city": "Arcadia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005576"
    },
    {
      "nct_id": "NCT00002070",
      "title": "Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cytomegalovirus Retinitis",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Sargramostim",
          "type": "DRUG"
        },
        {
          "name": "Ganciclovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Schering-Plough",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-09-04T03:23:43.050Z",
      "location_count": 14,
      "location_summary": "Los Angeles, California • San Francisco, California • Sherman Oaks, California + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Sherman Oaks",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002070"
    },
    {
      "nct_id": "NCT02620865",
      "title": "BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Pancreatic Adenocarcinoma",
        "Recurrent Pancreatic Carcinoma",
        "Stage III Pancreatic Cancer",
        "Stage IV Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Antibody Therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Leucovorin Calcium",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel Albumin-Stabilized Nanoparticle Formulation",
          "type": "DRUG"
        },
        {
          "name": "Sargramostim",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Barbara Ann Karmanos Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2015-12",
      "completion_date": "2021-06-21",
      "has_results": true,
      "last_update_posted_date": "2023-05-15",
      "last_synced_at": "2026-09-04T03:23:43.050Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02620865"
    },
    {
      "nct_id": "NCT00011934",
      "title": "Bone Marrow Transplantation Plus Biological Therapy in Treating Patients With Chronic Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "recombinant interferon alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "autologous bone marrow transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "12 Years to 70 Years"
      },
      "enrollment_count": null,
      "start_date": "1998-05",
      "completion_date": "2002-08",
      "has_results": false,
      "last_update_posted_date": "2014-04-17",
      "last_synced_at": "2026-09-04T03:23:43.050Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00011934"
    },
    {
      "nct_id": "NCT00003416",
      "title": "S9805, High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Followed by Interferon Alfa in Treating Patients With Waldenstrom's Macroglobulinemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "recombinant interferon alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "Up to 69 Years"
      },
      "enrollment_count": 9,
      "start_date": "1998-09",
      "completion_date": "2004-01",
      "has_results": false,
      "last_update_posted_date": "2015-03-06",
      "last_synced_at": "2026-09-04T03:23:43.050Z",
      "location_count": 84,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 55 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003416"
    },
    {
      "nct_id": "NCT00017290",
      "title": "Combination Chemotherapy Followed By Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "autologous immunoglobulin idiotype-KLH conjugate vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "keyhole limpet hemocyanin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        },
        {
          "name": "vincristine sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Genitope Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2000-11",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-12-04",
      "last_synced_at": "2026-09-04T03:23:43.050Z",
      "location_count": 21,
      "location_summary": "Dublin, California • Greenbrae, California • Los Angeles, California + 16 more",
      "locations": [
        {
          "city": "Dublin",
          "state": "California"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00017290"
    },
    {
      "nct_id": "NCT00014092",
      "title": "Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "recombinant interferon alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Saint Francis Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1999-12",
      "completion_date": "2003-12",
      "has_results": false,
      "last_update_posted_date": "2013-03-26",
      "last_synced_at": "2026-09-04T03:23:43.050Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Santa Monica, California • Aurora, Colorado",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00014092"
    },
    {
      "nct_id": "NCT00217373",
      "title": "Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Recombinant Interferon Alfa-2b",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Recombinant Vaccinia-CEA(6D)-TRICOM Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sargramostim",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2005-06",
      "completion_date": "2015-03",
      "has_results": false,
      "last_update_posted_date": "2015-04-20",
      "last_synced_at": "2026-09-04T03:23:43.050Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00217373"
    },
    {
      "nct_id": "NCT07027748",
      "title": "Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuroblastoma",
        "Neuroblastoma Recurrent",
        "Relapsed Neuroblastoma",
        "Refractory Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "Naxitamab",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Sargramostim granulocyte-macrophage colony stimulating factor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Steven DuBois, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "1 Year to 30 Years"
      },
      "enrollment_count": 18,
      "start_date": "2025-06-27",
      "completion_date": "2027-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-14",
      "last_synced_at": "2026-09-04T03:23:43.050Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07027748"
    },
    {
      "nct_id": "NCT00030342",
      "title": "Biological Therapy and Chemotherapy in Treating Patients With Metastatic Kidney Cancer or Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Kidney Cancer"
      ],
      "interventions": [
        {
          "name": "recombinant interferon alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic autologous lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "fluorouracil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "St. Luke's Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2001-11",
      "completion_date": "2008-01",
      "has_results": false,
      "last_update_posted_date": "2013-06-26",
      "last_synced_at": "2026-09-04T03:23:43.050Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00030342"
    }
  ]
}